Dr Jeremy Braybrooke
BSc, BM, FRCP, PhD
Senior Clinical Research Fellow
Jeremy is a Consultant Medical Oncologist and clinical lead for oncology at University Hospitals Bristol NHS Foundation Trust. He trained in Medical Oncology at the Cancer Research UK Medical Oncology unit in Oxford. During this time he completed a PhD in DNA damage and repair pathways. Jeremy has worked in Bristol since 2003 and developed a large research focussed clinical practice specialising in breast and testicular cancers. Jeremy sits on a NICE Technology Appraisal Committee evaluating new medicines and is a member of the Royal College of Physicians Specialist Advisory Committee for medical oncology training. He is actively involved in clinical research and since 2016 has worked part time as a Senior Clinical Research Fellow within EBCTCG.
Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials
Gray R. et al, (2018), CANCER RESEARCH, 78
18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.
Hall DO. et al, (2018), Nucl Med Commun, 39, 161 - 170
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2018), Lancet Oncol, 19, 27 - 39
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Pan H. et al, (2017), N Engl J Med, 377, 1836 - 1846
The mutational frequency of BRAF and KRAS in low-grade serous testicular neoplasms-a case series.
Gwiti P. et al, (2017), Histopathology, 71, 686 - 692